| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 3/gram
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Telmisartan |
| CAS NO. | 144701-48-4 |
| Specification | 99% |
| Appearance | white powder |
| Package | 1KG/Bag,25Kg/drum |
| MOQ | 1kg |
Telmisartan, chemical name 4′-[4-methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid, molecular formula C33H30N4O2, white or off-white crystalline powder, odorless and tasteless. It is soluble slightly soluble or dimethylformamide, very slightly soluble in ethanol, almost insoluble in water, easily soluble in 1 mol/L , and very slightly soluble in 0.1 mol/L
Usage and dosage
Adults: Individualized dosing is recommended. The usual initial dose is one tablet (40 mg) once a day. Within the dose range of 20 to 80 mg, the antihypertensive effect of telmisartan is dose-dependent. If the ideal blood pressure is not achieved after medication, the dose can be increased, with a maximum dose of 80 mg once a day.
This product can be used in combination with thiazide diuretics such as hydrochlorothiazide. This type of diuretic has a synergistic antihypertensive effect with this product.
Because telmisartan can only achieve its maximum effect four to eight weeks after the start of treatment, this should be taken into consideration if the drug dose is to be increased.
Patients with renal insufficiency Patients with mild or moderate renal insufficiency: No dose adjustment is required for taking this product. Telmisartan is not eliminated by blood filtration.
Patients with hepatic insufficiency Patients with mild or moderate hepatic insufficiency: The daily dose of this product should not exceed 40 mg. Elderly people do not need to adjust the dose of this product.
Children and adolescents For children and adolescents under 18 years of age: The safety and efficacy data of this product have not been established.
| Items | Standards | Results |
| Physical Analysis | ||
| Appearance | white powder | Complies |
| Specification | 99% | Complies |
| Mesh Size | 100 % pass 80 mesh | Complies |
| Ash | ≤ 5.0% | 2.85% |
| Loss on Drying | ≤ 5.0% | 2.85% |
| Chemical Analysis | ||
| Heavy Metal | ≤ 10.0 mg/kg | Complies |
| Pb | ≤ 2.0 mg/kg | Complies |
| As | ≤ 1.0 mg/kg | Complies |
| Hg | ≤ 0.1 mg/kg | Complies |
| Microbiological Analysis | ||
| Total Plate Count | ≤ 1000cfu/g | Complies |
| Yeast&Mold | ≤ 100cfu/g | Complies |
| E.coil | Negative | Negative |
| Salmonella | Negative | Negative |
| Conclusion: in conformity with the enterprise standard | ||
Product use
Non-peptide angiotensin II receptor antagonist, which can selectively and irreversibly block ATI receptors without affecting other receptor systems. For mild to moderate hypertension. Telmisartan is a new type of antihypertensive drug, a specific angiotensin II receptor (AT type) antagonist, used to treat essential hypertension. It replaces angiotensin II receptors and binds to AT receptor subtypes (known angiotensin II action sites) with high affinity. Telmisartan has no agonist effect at any site on the AT receptor site, and selectively binds to the AT receptor, and the binding effect is long-lasting. It has no affinity for other receptors (including AT2 and other AT receptors with fewer characteristics). The functions of the above other receptors are not yet known, and the receptor overstimulation effect that may be caused by the increase in angiotensin II levels caused by telmisartan is also unknown. Telmisartan does not inhibit human plasma renin, nor does it block ion channels. It does not inhibit angiotensin-converting enzyme II, which can also degrade bradykinin and cause adverse reactions. In humans, 80 mg of telmisartan can almost completely inhibit the increase in blood pressure caused by angiotensin II. The inhibitory effect lasts for 24 hours and can still be measured after 48 hours. The antihypertensive effect gradually becomes obvious within 3 hours after the first dose. The maximum antihypertensive effect can be obtained 4 weeks after the start of treatment and can be maintained in long-term treatment. If the treatment is suddenly interrupted, blood pressure will gradually return to the pre-treatment level after a few days without rebound hypertension. In a clinical trial study directly comparing two antihypertensive drugs, the incidence of dry cough in the treatment group was significantly lower than that in the angiotensin-converting enzyme inhibitor treatment group.
){kind=link}